HC-7366 by Hibercell for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HC-7366 overview

HC-7366 is under development for the treatment of colorectal cancer (CRC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), transitional cell carcinoma of the bladder (TCC), acute myelocytic leukemia (AML) and other solid tumors. The drug candidate contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate in a immidiate release oral formulation administerd via oral route. It is being developed based on QuAD Platform. It acts by targeting eIF-2-Alpha Kinase GCN2.

Hibercell overview

Hibercell is a biotechnology company that discovers and develops therapies for treatment of cancer. The company is investigating odetiglucan, an immune modulator candidate that enhances immune functions for the treatment of CRC-based liver Metastasis, pancreatic cancer and liver metastasis. It is also developing adaptive stress response modulator programs, HC-5404 for treatment of renal cell carcinoma, gastric cancer and others advanced solid tumors and HC-7366 to treat head and neck, colorectal and bladder cancer. Hibercell is headquartered in New York, the US.

For a complete picture of HC-7366’s drug-specific PTSR and LoA scores, buy the report here.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.